Skip to content
Logo text: ISPOR Improving healthcare decisions

Health Technology Assessment Central

The HTA Resource Center for Informing Healthcare Decisions

  • Home
  • What Is HTA?
  • HTA News and Events
  • Resource Library
  • Governance
  • Policy Interchange
  • Training and Development
« Back to ISPOR.org

News

CVS sets a cost-effectiveness threshold for health plan coverage of most new drugs

August 24, 2018

https://www.statnews.com/pharmalot/2018/08/14/cvs-cost-effectiveness-new-drugs/

Posted in: Uncategorized

Post navigation

← Irish HTA Official Calls for All New Patients to Start With Biosimilars
Professor says HSE should ‘take seriously’ cheaper medicines →

News

The new definition of HTA: A milestone in international collaboration
Impact of a Global Pandemic on Health Technology Assessment
NEW HTAi – ISPOR Joint Deliberative Processes for HTA Task Force
Strategic collaboration announced by NICE and Health Technology Wales
NICE and LSE announce new Executive MSc in Evaluation of Health Care Interventions and Outcomes degree program, starting in April 2020
Why HTA and Pooled Purchasing Must Be at the Heart of Global Health Transitions
Health Technology Assessment Around the World: Broadening the Understanding of Cross-Country Differences
Ghana’s HTA agenda and UHC, what difference could HTA make?
AMCP releases the AMCP Format for Formulary Submissions, version 4.1
The ‘Top 10’ Challenges for Health Technology Assessment: INAHTA Viewpoint

Twitter

Tweets about #HTA

#HTA

jelvidge_HEJamie Elvidge@jelvidge_HE·
3h

Enjoyed meeting more @HTx_H2020 collaborators this morning to discuss our work plan. Delighted to have joined such an engaged and enthusiastic team. Lots of helpful feedback, and now lots of work to do! #HTA

Reply on Twitter 1367827061352652802Retweet on Twitter 1367827061352652802Like on Twitter 1367827061352652802Twitter 1367827061352652802
decide_healthDecide@decide_health·
4h

And now the treat of the week...end: make sure you have some quality time to appreciate the high-impact insight from @CGDev brilliant #health expert team: #HTA to bolster value delivery amidst the #COVID19 Crisis. A thought provoking piece! https://decidehealth.world/en/news/cgd-expert-perspective-hta-bolster-value-delivery-amidst-covid-19-crisis

Reply on Twitter 1367810550760083456Retweet on Twitter 13678105507600834561Like on Twitter 1367810550760083456Twitter 1367810550760083456
jelvidge_HEJamie Elvidge@jelvidge_HE·
8h

The CDG blog focuses on vaccines, the same issues apply to diagnostics and treatments: "important decisions will be made anyway [with or w/o an econ evaluation], potentially misallocating substantial resources".
--> Lots of room for innovation in #HTA. #methodsmatter

Reply on Twitter 1367761028621209600Retweet on Twitter 1367761028621209600Like on Twitter 1367761028621209600Twitter 1367761028621209600
Load More...
Privacy Policy | Disclaimer
Copyright © 2021 ISPOR – The Professional Society for Health Economics and Outcomes Research